Status:
RECRUITING
INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND)
Lead Sponsor:
RAND
Collaborating Sponsors:
Arizona State University
National Institute of Mental Health (NIMH)
Conditions:
HIV/AIDS
Medication Adherence
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Low medication adherence when initiating antiretroviral treatment (ART) is a key barrier to HIV virologic suppression, resulting in avoidable cases of drug resistance, death, and viral transmission. R...
Detailed Description
Building on a previous R34 study, the investigators will adapt and deliver the INMIND approach to 550 ART initiators at Mildmay. Participants will initially be randomized to receive either usual care ...
Eligibility Criteria
Inclusion
- Male and female clients age 18 and older.
- Started ART at Mildmay or another clinic within the preceding 2 months
- Able to speak and understand either English or Luganda.
- Have their own cell phone or have consistent access to someone else's phone.
- Willing to receive daily text messages for the 6 months of intervention duration.
- Willing and able to use the WisePill device distributed for adherence verification for the duration of the study.
Exclusion
- Not mentally fit to consent.
- Language other than Luganda or English.
- Not willing to consistently use the Wisepill device for adherence measurement.
Key Trial Info
Start Date :
April 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2029
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT06949774
Start Date
April 2 2025
End Date
October 31 2029
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mildmay Uganda
Kampala, Uganda, 24985